Literature DB >> 6394721

Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G.

K Heininger, U G Liebert, K V Toyka, F T Haneveld, G Schwendemann, V Kolb-Bachofen, H G Ross, S Cleveland, U A Besinger, E Gibbels.   

Abstract

In chronic (relapsing) inflammatory polyneuropathy (CRIP), successful treatment with plasma exchange has led to the concept of pathogenic humoral factors. In 6 patients with CRIP, 5 of whom improved after plasma exchange, the potential pathogenic role of circulating immunoglobulin (Ig) fractions was tested by applying the systemic passive transfer model to marmoset monkeys. After continuous treatment with intramuscular injections for 2-8 weeks, monkeys injected with the crude immunoglobulin fractions or with purified IgG from 5 of the 6 patients showed a significant and partially reversible reduction of the motor nerve conduction velocity (mean 34%, P less than 0.001) when compared with pre-treatment values. In control animals the reduction was 4%. Morphological examination revealed only minor ultrastructural changes of the myelin sheath. Immunocytochemistry revealed that human IgG was able to cross the blood-nerve barrier. It is concluded that the circulating IgG-fraction of patients with CRIP contains a factor that may contribute to the disordered nerve function after crossing the blood-nerve barrier. It may be the removal of this particular factor which is responsible for the rapid recovery of nerve conduction in patients after plasma exchange.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6394721     DOI: 10.1016/0022-510x(84)90136-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 2.  Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Avinash Chandra Singh
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

Review 3.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

4.  Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis.

Authors:  G Stoll; G Schwendemann; K Heininger; W Köhne; H P Hartung; R Seitz; K V Toyka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

5.  The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system.

Authors:  R J Seitz; K Heininger; G Schwendemann; K V Toyka; W Wechsler
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

6.  Passive transfer studies in demyelinating neuropathy with IgM monoclonal antibodies to myelin-associated glycoprotein.

Authors:  A J Steck; N Murray; J C Justafre; C Meier; K V Toyka; K Heininger; G Stoll
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

7.  Immunocytochemical studies of serum proteins and immunoglobulins in human sural nerve biopsies.

Authors:  U G Liebert; R J Seitz; T Weber; W Wechsler
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

Review 8.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Richard A C Hughes; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2015-08-25

Review 9.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

10.  Terminal complement activation is increased and associated with disease severity in CIDP.

Authors:  Isaak Quast; Christian W Keller; Falk Hiepe; Björn Tackenberg; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2016-07-25       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.